Neurogene Inc. (NASDAQ:NGNE) reported that Chief Scientific Officer Stuart Cobb sold 6,797 shares of common stock on March 13, 2026, for roughly $141,445 in aggregate proceeds. The transactions were executed in multiple trades at prices ranging from $19.94 to $22.16 per share, according to the company disclosure.
At the time of those sales the stock was trading at $21.08 and has recorded an 8.6% decline over the prior week, reflecting continued volatility in the share price for the biotech firm. The reported transactions were made pursuant to a pre-arranged 10b5-1 trading plan that Cobb adopted on February 6, 2025.
Following the March 13 trades, Cobb's direct holdings stand at 30,497 shares of Neurogene common stock, as shown in the Form 4 filing with the Securities and Exchange Commission.
Beyond the insider transactions, Neurogene has continued to advance its lead gene therapy candidate, NGN-401. The U.S. Food and Drug Administration granted Breakthrough Therapy designation for NGN-401 in Rett syndrome based on interim efficacy and safety results from the Phase 1/2 trial. The filing noted functional improvements across multiple domains of Rett syndrome in the interim dataset.
The company has also dosed multiple participants in its Embolden registrational trial for NGN-401 and plans to complete dosing by the second quarter of 2026. Neurogene intends to present interim data from the Phase 1/2 study by mid-2026; that interim dataset will include at least 12 months of follow-up for all participants enrolled.
Market analysts have taken note of these clinical and regulatory developments. Stifel reiterated a Buy rating on Neurogene, citing what it describes as a viable safety margin and identifying completion of dosing as a potential clearing event for the company. Separately, Citizens maintained a Market Outperform rating on Taysha Gene Therapies while calling out favorable prospects for both Taysha and Neurogene as they move toward registrational programs.
For investors seeking additional context, InvestingPro subscribers can access 11 additional ProTips for NGNE along with comprehensive analysis ahead of the company’s earnings report scheduled for March 19.
Taken together, the insider sale and the timing of multiple clinical readouts underscore a period of active corporate and regulatory activity for Neurogene as it advances NGN-401 through registrational work and prepares for upcoming data releases.